~~<i id='CFED639438'><strike id='CFED639438'><tt id='CFED639438'><pre id='CFED639438'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：Wikipedia 2025-10-01 20:30:49 Page View：5

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： UK homeowners get some respite as inflation falls by more than anticipated to a 15
Next article： Medicare proposal to cover medical devices draws a mixed reaction

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

UK homeowners get some respite as inflation falls by more than anticipated to a 15

SadieJames,right,andJonTaylor,adebtmanageratthecharityChristiansAgainstPoverty,readthedocumentsfroma

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

FILE-RichardMoore,theChiefofBritain'sSecretIntelligenceService,alsoknownasMI6,answersquestionsafterg